Dr. Barbara Burtness is Professor of Medicine at the Yale University School of Medicine, Interim Associate Cancer Center Director, Diversity, Equity, and Inclusion; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center; and Director of the Yale Head and Neck SPORE. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicenter trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers. She has conducted numerous phase I–III investigator-initiated trials. Dr. Burtness’ research focuses on translational studies in head and neck cancer, including biomarkers of resistance to EGFR inhibition and synthetic lethal approaches for Fanconi Anemia-related head and neck cancer.